DE60217107D1 - Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung - Google Patents

Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung

Info

Publication number
DE60217107D1
DE60217107D1 DE60217107T DE60217107T DE60217107D1 DE 60217107 D1 DE60217107 D1 DE 60217107D1 DE 60217107 T DE60217107 T DE 60217107T DE 60217107 T DE60217107 T DE 60217107T DE 60217107 D1 DE60217107 D1 DE 60217107D1
Authority
DE
Germany
Prior art keywords
deposit
polypeptide
multiple copies
multantigenic
epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60217107T
Other languages
English (en)
Other versions
DE60217107T2 (de
Inventor
Beka Solomon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of DE60217107D1 publication Critical patent/DE60217107D1/de
Application granted granted Critical
Publication of DE60217107T2 publication Critical patent/DE60217107T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60217107T 2001-06-20 2002-06-20 Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung Expired - Fee Related DE60217107T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29920101P 2001-06-20 2001-06-20
US299201P 2001-06-20
US37171702P 2002-04-12 2002-04-12
US371717P 2002-04-12
PCT/US2002/019567 WO2003000719A2 (en) 2001-06-20 2002-06-20 Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same

Publications (2)

Publication Number Publication Date
DE60217107D1 true DE60217107D1 (de) 2007-02-08
DE60217107T2 DE60217107T2 (de) 2007-08-23

Family

ID=26971089

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60217107T Expired - Fee Related DE60217107T2 (de) 2001-06-20 2002-06-20 Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung

Country Status (10)

Country Link
US (1) US20050053575A1 (de)
EP (1) EP1397380B1 (de)
AT (1) ATE349468T1 (de)
AU (1) AU2002310474A1 (de)
CA (1) CA2450783A1 (de)
DE (1) DE60217107T2 (de)
DK (1) DK1397380T3 (de)
ES (1) ES2279869T3 (de)
PT (1) PT1397380E (de)
WO (1) WO2003000719A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477675C (en) 2002-03-05 2013-05-21 Ramot At Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein
EP1911765A3 (de) * 2002-07-24 2008-04-23 Innogenetics N.V. Vorbeugung, Behandlung und Diagnose von Erkrankungen im Zusammenhang mit Beta-Amyloid-Bildung und/oder -Aggregation
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
CN101171031B (zh) * 2005-05-05 2011-09-28 默沙东公司 防止和治疗阿尔茨海默病的肽偶联物组合物和方法
EP1987361A4 (de) * 2006-01-30 2009-03-04 Invitrogen Corp Zusammensetzungen und verfahren zur erkennung und quantifizierung toxischer substanzen in krankheitsstadien
US8715684B2 (en) 2007-08-28 2014-05-06 Ramot At Tel Aviv University Ltd. Peptides inducing a CD4i conformation in HIV gp120 while retaining vacant CD4 binding site
WO2009079566A2 (en) * 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
US9241987B2 (en) 2009-11-20 2016-01-26 The University Of Chicago Methods and compositions related to immunogenic fibrils
US9289488B2 (en) 2010-08-12 2016-03-22 Ac Immune Sa Vaccine engineering
CA2813833C (en) 2010-10-26 2020-09-22 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
JP5917682B2 (ja) 2011-04-22 2016-05-18 ワイス・エルエルシー 変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
CA2172305A1 (en) * 1995-03-30 1996-10-01 Muneo Aoyama Multiple antigenic peptide comprising at least two hepatitis c virus-associated peptides
EP0861900A1 (de) * 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunologischer Nachweis von Prionen
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
DE19838751A1 (de) * 1998-08-26 2000-03-09 Hubert Kalbacher Verfahren zur Herstellung einer Affinitätsmatrix, Zwischenerzeugnis zur Herstellung und Anwendung der Affinitätsmatrix
US6787637B1 (en) * 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
JP2003503591A (ja) * 1999-06-29 2003-01-28 ダコ エー エス 標識およびプローブを保持するデンドリマーを用いた検出

Also Published As

Publication number Publication date
EP1397380A2 (de) 2004-03-17
ATE349468T1 (de) 2007-01-15
ES2279869T3 (es) 2007-09-01
WO2003000719A3 (en) 2003-12-11
AU2002310474A1 (en) 2003-01-08
DK1397380T3 (da) 2007-05-07
WO2003000719A2 (en) 2003-01-03
WO2003000719A8 (en) 2004-02-19
PT1397380E (pt) 2007-04-30
DE60217107T2 (de) 2007-08-23
US20050053575A1 (en) 2005-03-10
EP1397380B1 (de) 2006-12-27
CA2450783A1 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
DE60217107D1 (de) Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung
AU2019250206A1 (en) Novel immunogenic peptides
NO20083805L (no) Anvendelse av et antistoff som binder Aβ-peptidsekvenser
AR035119A1 (es) Anticuerpos humanos antagonistas anti-htnfsf13b
NO20053862L (no) Aktiv immunisering for a danne antistoffer mot loselig A-beta
ATE413189T1 (de) Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
ATE469176T1 (de) Modifizierter anti-tnf antikörper
NO20063026L (no) Antistoffer
TNSN06273A1 (en) Identification of self and non-self antigens implicated in autoimmune diseases
DE69526339D1 (de) Monoklonale antikörper, die an den vorläufer des tumorabstossantigen mage-1 anbinden, rekombinantes mage-1, und von mage-1 abgebieteteimmunogene peptide
AR075047A1 (es) Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit.
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
DE69133242D1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
PH12020551648A1 (en) Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof
AU2004290085A1 (en) Antibodies against secretoryleukocyte protease inhibitor
EP0972054A4 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
DE60319350D1 (de) Gemeinsame epitope von antigenen aus einer multigen-familie
EA202192865A1 (ru) Лечение головной боли с использованием антител к cgrp
TNSN08184A1 (en) Chimeric antigens and vaccines
LT2002051A (en) Mimetic peptides for epitope of apoliprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
ZA202205813B (en) Trpv1 epitopes and antibodies
RU2005120785A (ru) Способы и средства для лечения воспалительных состояний с помощью полипептида, содержащего собственные и чужеродные аминокислотные сегменты
ATE525470T1 (de) Antigene epitope des faktors viii, inhibitoren dagegen, und deren verwendungen
Minassian et al. Efficacy of the novel Plasmodium falciparum blood-stage vaccine RH5. 1/AS01B in a phase I/IIA clinical trial

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee